Zacks: Analysts Expect TG Therapeutics Inc (NASDAQ:TGTX) to Announce -$0.37 Earnings Per Share

Analysts predict that TG Therapeutics Inc (NASDAQ:TGTX) will announce earnings per share (EPS) of ($0.37) for the current quarter, according to Zacks. Two analysts have made estimates for TG Therapeutics’ earnings, with estimates ranging from ($0.40) to ($0.34). TG Therapeutics posted earnings per share of ($0.43) in the same quarter last year, which would indicate a positive year-over-year growth rate of 14%. The firm is scheduled to announce its next quarterly earnings report on Friday, November 8th.

According to Zacks, analysts expect that TG Therapeutics will report full year earnings of ($1.53) per share for the current year, with EPS estimates ranging from ($1.64) to ($1.30). For the next fiscal year, analysts anticipate that the firm will post earnings of ($1.27) per share, with EPS estimates ranging from ($1.60) to ($0.87). Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that follow TG Therapeutics.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Friday, August 9th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.43) by $0.01. The company had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.04 million. TG Therapeutics had a negative return on equity of 415.54% and a negative net margin of 94,751.79%.

Several analysts recently issued reports on TGTX shares. ValuEngine upgraded TG Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Cantor Fitzgerald reiterated a “buy” rating and set a $17.00 price objective on shares of TG Therapeutics in a report on Monday, May 13th. B. Riley reiterated a “buy” rating on shares of TG Therapeutics in a report on Tuesday, June 11th. BidaskClub upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday. Finally, Zacks Investment Research upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $14.07.

Shares of NASDAQ:TGTX opened at $6.55 on Friday. The company has a current ratio of 1.72, a quick ratio of 1.72 and a debt-to-equity ratio of 1.89. TG Therapeutics has a 1 year low of $3.32 and a 1 year high of $12.90. The business has a fifty day simple moving average of $7.71 and a 200 day simple moving average of $7.06.

In other TG Therapeutics news, CEO Michael S. Weiss bought 50,000 shares of the stock in a transaction on Wednesday, June 26th. The shares were purchased at an average cost of $7.04 per share, with a total value of $352,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Sean A. Power sold 17,654 shares of the stock in a transaction on Monday, July 1st. The stock was sold at an average price of $8.47, for a total transaction of $149,529.38. The disclosure for this sale can be found here. 14.20% of the stock is currently owned by company insiders.

A number of institutional investors have recently bought and sold shares of TGTX. Camber Capital Management LP acquired a new position in TG Therapeutics during the second quarter worth $8,650,000. Sofinnova Investments Inc. increased its position in TG Therapeutics by 258.5% during the second quarter. Sofinnova Investments Inc. now owns 1,261,384 shares of the biopharmaceutical company’s stock worth $10,911,000 after buying an additional 909,573 shares during the last quarter. BlackRock Inc. increased its position in TG Therapeutics by 19.5% during the second quarter. BlackRock Inc. now owns 5,304,463 shares of the biopharmaceutical company’s stock worth $45,883,000 after buying an additional 866,572 shares during the last quarter. Vanguard Group Inc. increased its position in TG Therapeutics by 19.7% during the second quarter. Vanguard Group Inc. now owns 4,041,122 shares of the biopharmaceutical company’s stock worth $34,955,000 after buying an additional 665,380 shares during the last quarter. Finally, Deutsche Bank AG increased its position in TG Therapeutics by 72.2% during the fourth quarter. Deutsche Bank AG now owns 824,164 shares of the biopharmaceutical company’s stock worth $3,378,000 after buying an additional 345,477 shares during the last quarter. 54.48% of the stock is currently owned by hedge funds and other institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing.

See Also: Penny Stocks, What You Need To Know

Get a free copy of the Zacks research report on TG Therapeutics (TGTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.